A new weight-loss jab will be rolled out on the NHS in England - but it could take 12 years for everyone to receive it, the NHS drugs advisory body says. The National Institute for Health and Care Excellence (NICE) final draft guidance on Mounjaro has recommended it starts being given from March, alongside advice on diet and exercise.

Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time. Zepbound,

England’s National Health Service will begin rolling out Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro over the next few months, though the medication will initially be made available to only a small proportion of the patients who could benefit from it.

Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.

New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new efforts to market the drug as shortages ease.Recent months have brought new questions about whether the sky-high expectations for Zepbound’s sales—which have sent Lilly’s share price up more than 230% over the past three years—may be overly optimistic.

The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible, and alongside a specialized diet.

Eli Lilly (LLY) stock is rising after the company said its weight-loss drug achieved better results than Wegovy

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative areas of the pharmaceutical indus